Next Article in Journal
Mice Condition Cephalic-Phase Insulin Release to Flavors Associated with Postoral Actions of Concentrated Glucose
Previous Article in Journal
The Combined Effects of the Most Important Dietary Patterns on the Incidence and Prevalence of Chronic Renal Failure: Results from the US National Health and Nutrition Examination Survey and Mendelian Analyses
Previous Article in Special Issue
Exploring the Impact of French Raw-Milk Cheeses on Oxidative Process Using Caenorhabditis elegans and Human Leukocyte Models
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Nutrients
Volume 16
Issue 14
10.3390/nu16142249
nutrients-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

A Diet Lacking Selenium, but Not Zinc, Copper or Manganese, Induces Anticancer Activity in Mice with Metastatic Cancers

by
Patricia Díaz-Ortega
,
José Manuel Calderón-Montaño
,
Julio José Jiménez-Alonso
,
Emilio Guillén-Mancina
,
Víctor Jiménez-González
,
Estefanía Burgos-Morón
and
Miguel López-Lázaro
*
Department of Pharmacology, Faculty of Pharmacy, University of Seville, 41012 Sevilla, Spain
*
Author to whom correspondence should be addressed.
Nutrients 2024, 16(14), 2249; https://doi.org/10.3390/nu16142249
Submission received: 7 June 2024 / Revised: 9 July 2024 / Accepted: 10 July 2024 / Published: 12 July 2024
(This article belongs to the Special Issue Association between Diet and Oxidative Stress)
Browse Figures
Versions Notes

Abstract

:
Selenium, zinc, copper, and manganese are essential components of antioxidant enzymes involved in the elimination of reactive oxygen species (ROS). Given that cancer cells produce high levels of ROS and the accumulation of ROS can lead to cell death, cancer cells may be susceptible to strategies that reduce ROS elimination. In this work, we prepared several artificial diets that contained normal carbohydrate, protein, and lipid levels but lacked selenium, zinc, copper, or manganese. The anticancer activity of these diets was examined in a metastatic ovarian cancer model, established by injecting ID8 Trp53−/− murine ovarian cancer cells into the peritoneal cavity of C57BL/6JRj mice. Treatments started 15 days later and consisted of replacing a normal diet with one of the artificial diets for several weeks. A significant improvement in mice survival was observed when the normal diet was replaced with the selenium-free diet. Diets lacking zinc, copper, or manganese showed no significant impact on mice survival. All diets were very well tolerated. The anticancer efficacy of a diet lacking selenium was confirmed in mice with metastatic colon cancer and in mice with metastatic triple-negative breast cancer. These results suggest that diets lacking selenium hold potential for the treatment of metastatic cancers.

1. Introduction

Despite advances in anticancer therapies, survival rates for patients with metastatic cancers remain low. For instance, the five-year relative survival rates for stage IV breast, prostate, ovarian, colon, lung, liver, and pancreatic cancers are 31%, 34%, 32%, 14%, 8%, 4%, and 3%, respectively [1]. Many patients who survive five years after diagnosis still succumb to the disease. A key reason for these low survival rates is the limited ability of current pharmacological treatments to selectively target cancer cells without harming normal cells. When treatment selectivity is suboptimal, oncologists often must administer the drugs at the maximum tolerated dose, rather than the effective dose, which is frequently insufficient for eradicating cancer cells. If oncologists were to administer the doses necessary to eradicate cancer cells, such doses would also have lethal effects on normal cells, ultimately leading to patient death. Identifying selective treatments could enhance cancer cell eradication and improve survival rates among patients with metastasis [2,3].
A potential strategy for achieving selective anticancer therapy involves upregulating the levels of reactive oxygen species (ROS) within cancer cells. It is well established that cancer cells produce high ROS levels relative to normal cells [4,5]. Evidence suggests that increasing ROS levels in cancer cells offers potential for targeted elimination, because the comparatively lower basal ROS levels in healthy cells serve as a safeguard against reaching toxic thresholds [4,5,6,7]. This anticancer strategy may be implemented by directly increasing ROS production or, alternatively, by decreasing ROS elimination capacity. Cancer cells use antioxidant enzymes, such as peroxidases, superoxide dismutase (SOD), and thioredoxin reductases, to eliminate ROS. These enzymes depend on essential minerals like selenium, zinc, copper, and manganese. One potential anticancer approach involves dietary deprivation of these micronutrients to suppress the enzymatic detoxification system, causing ROS accumulation in cells and selectively inducing cytotoxicity in cancer cells [5].
However, this anticancer approach might cause toxicity since these micronutrients have important physiological functions. For instance, selenium regulates several selenium-dependent enzymes known as selenoproteins. Unlike other enzymes regulated by micronutrients, selenoproteins incorporate selenium cotranslationally. The amino acid selenocysteine is integrated into elongating proteins during translation to form functional selenoproteins [8]. Examples of selenoproteins include glutathione peroxidases, thioredoxin reductases, iodothyronine deiodinases, and selenoprotein P. Glutathione peroxidases are key antioxidant enzymes; they play a crucial role in immune response, thyroid function, and reproductive processes in humans by coordinating antioxidant defense mechanisms [9,10,11,12]. Zinc, an essential micronutrient, is vital for many cellular processes such as growth, immune function, neurotransmission, vision, and reproduction. Over 3000 proteins in humans have zinc-binding sites, playing catalytic, structural, and regulatory roles. Catalytically, zinc supports many enzymes involved in numerous chemical reactions. For example, it catalyzes reactions through the enzyme Cu/Zn superoxide dismutase (Cu/Zn SOD), which detoxify superoxide anions. Structurally, zinc stabilizes proteins like zinc finger motifs, which are crucial for DNA binding and gene regulation. Metallothioneins, which bind zinc, help regulate metal ions, defend against oxidative stress, and detoxify heavy metals. Zinc also influences gene expression, cell signaling, hormone release, and nerve impulse transmission [13,14,15]. Copper plays a vital role in neutralizing free radicals and redox reactions. It is a component of cuproenzymes, including Cu/Zn SOD, which reduces superoxide anions to hydrogen peroxide (H2O2). In turn, other antioxidant enzymes such as glutathione peroxidases and iron-dependent catalase further reduce H2O2 to water, contributing to cellular antioxidant defense mechanisms [16,17,18,19]. Manganese plays a crucial role in the manganese superoxide dismutase (MnSOD) enzyme, a key mitochondrial antioxidant that converts superoxide radicals into hydrogen peroxide. MnSOD is also involved in several metabolic processes, including glucose and lipid metabolism, protein synthesis, skeletal growth, reproduction, and immune function [20]. The Recommended Daily Allowance (RDA) values for these micronutrients in different situations, along with the possible consequences of their deficiencies in humans, have been extensively reviewed by the Linus Pauling Institute’s Micronutrient Information Center [21]. The RDA of selenium is 55 μg/day for adults, the RDA for zinc is 8 mg/day for adult women and 11 mg/day for adult men, the RDA for copper is 900 μg/day for adults, and the RDA for manganese is 2.3 mg/day for adult men and 1.8 mg/day for adult women. The anticancer activity of selenium [22,23,24], zinc [25,26], copper [27,28,29], and manganese [24,30] has been reviewed previously. Several investigations have also shown that cancer patients frequently present with altered serum levels of these micronutrients, and these variations have been correlated with patient survival rates [31,32,33,34].
While sustained depletion of selenium, zinc, copper, or manganese may lead to toxicity, transient depletion could induce anticancer activity without toxic effects. Cancer cells, due to their higher ROS production, may rely more heavily on these micronutrients for antioxidant defense, making transient depletion of these elements a potential strategy to selectively induce cell death in cancer cells without harming normal cells. This study aims to evaluate the anticancer efficacy and tolerability of eliminating these micronutrients from the diet for several weeks. Our results demonstrate for the first time that a diet lacking selenium, but not zinc, copper, or manganese, increases the survival rates of mice with metastatic cancers, without causing toxicity in the animals.

2. Materials and Methods

2.1. Cell Culture and Drugs

CT26.WT (murine colorectal cancer cells, CRL-2638) and 4T1 (murine triple-negative breast cancer cells, CRL-2539), were obtained from the American Type Culture Collection (ATCC, Manassas, VA, USA). ID8 Trp53−/− (murine ovarian cancer cells) were a gift from Dr. Iain A. McNeish (Institute of Cancer Sciences, University of Glasgow, Glasgow, UK) [35]. 4T1 and CT26.WT cells were cultured in RPMI 1640, which was supplemented with 100 U/mL penicillin, 100 μg/mL streptomycin, and 10% fetal bovine serum (FBS). ID8 Trp53−/− were grown in Dulbecco’s modified Eagle’s medium (DMEM) high-glucose medium, which was supplemented with 0.11 g/L sodium pyruvate, 4% FBS, and 1% insulin–transferrin–selenium. All cells were cultured in a humidified 37 °C incubator with 5% CO2. Cisplatin was purchased from Thermo Scientific Acros Organics (Waltham, MA, USA), and capecitabine (500 mg/tablet, Normon, Madrid, Spain) was obtained from a local pharmacy (Seville, Spain).

2.2. Animals

Female C57BL/6JRj mice (n = 70) and female BALB/cAnNRj mice (n = 50), 10 weeks or older, were obtained from Janvier Labs® (Le Genest-Saint-Isle, France). To allow adequate acclimation, the mice were housed in our animal laboratory facilities for at least two weeks before the start of the experiments. The animals were maintained under standard conditions, including a 12 h light/12 h dark cycle, 70–75% humidity, and a temperature of 24 °C, with ad libitum access to food and water. The mice were provided with a standard diet (ssniff diet R/M-Z E/R/S; V1724-000, ssniff Spezialdiäten, Soest, Germany). At the beginning of the experiments, all mice were 12 weeks or older. The experiments were approved by the Animal Ethics Committee of the University of Seville (CEEA-US2018-6/2 and CEEA-US2019-20) and Junta de Andalucía (15/05/2018/090 and 13/11/2020/131) and were conducted following the recommendations of the European Union on animal experimentation (Directive of the European Council 2010/630/EU).

2.3. In Vivo Cancer Models

In the three cancer models used in this study, murine cells (9th–11th passage) were cultured in a 75 cm2 flask until reaching approximately 60–70% confluence. The medium was removed, and the cells were washed twice with sterile PBS. Then, the cells were incubated with trypsin/EDTA solution for 1–3 min at 37 °C, and the cells were suspended in 5 mL of sterile PBS. The cell suspension was pipetted up and down to break up any cell aggregates before adding 2.5% FBS-supplemented medium. A working cell suspension (ranging between 1 × 105 and 5 × 106 cells/mL, depending on the cancer model) was prepared. The cell suspension was centrifuged (250× g) at room temperature for 5 min, and the medium was removed. The cells were suspended in warm sterile filtered PBS and recounted to ensure the correct cell density. Finally, a 1 mL syringe was filled with 0.2 mL of the working cell suspension and injected into the peritoneal cavity or the tail vein of the mice.
One day before initiating the treatments, the mice were randomly assigned to different groups (randomization within blocks; the cage position on the racks was not randomized). The sample size was determined to ensure representative results, based on the experimental model and outcomes from previous experiments. Researchers were aware of group allocation during the experiments and data analysis. No injected mice were excluded unless specified. Untreated animals (control group) continued to receive their standard diet (ssniff diet). In the positive control group, mice were administered the maximum tolerated doses of an anticancer drug used in patients with the specific type of cancer under investigation (Table 1). For the groups of mice treated with the experimental diets, the treatment involved replacing their regular diet with one of the experimental diets. Depending on the model, treatments began four or fifteen days after injecting the cancer cells, allowing time for the cells to adapt to the new environment and proliferate before the start of the treatments. The objective of our research was not to prevent metastasis but to explore new treatments for patients with established metastatic cancers. The diet treatment lasted at least 6 weeks, unless otherwise specified. After the treatment period, the surviving animals returned to their normal diet. A summary of the three in vivo cancer models used in this study is provided in Table 1.
In the ovarian cancer model, 5 × 106 ID8 Trp53−/− cells were injected into the peritoneal cavity of female C57BL/6JRj mice [35]. Treatments started 15 days after the cancer cell inoculation. The positive control, cisplatin (5 mg/kg), was administered intraperitoneally once a week for 4 weeks.
The colon cancer model was established by injecting 105 CT26.WT cells into the tail vein of female BALB/cAnNRj mice [36,37]. Treatments began 4 days after cancer cell inoculation. Capecitabine (450 mg/kg/day) was employed as a positive control and was administered in the diet following a schedule of 7 days on and 7 days off (7/7) to maximize the anticancer activity of this drug [38]. The animals received 2 or 3 cycles depending on their state of health at the moment of initiating the third capecitabine cycle. To prepare the capecitabine treatment, we powdered the standard diet (ssniff diet) and added capecitabine at a dose of 2500 mg/kg of diet; then, we added water to make a soft dough, which was pelleted and left to air-dry until use. A 25 g mouse typically consumed an average of 4.5 g of diet per day, resulting in a capecitabine dose of approximately 450 mg/kg/day.
In the triple-negative breast cancer model, female BALB/cAnNRj mice were inoculated with 105 4T1 cancer cells in the tail vein [39,40]. Treatments were initiated 4 days after the injection of the cells. The positive control, cisplatin (5 mg/kg), was administered intraperitoneally once a week for 4 weeks.
In the three models, all animals underwent daily monitoring, with body weights measured at least three times a week. Mice were humanely euthanized via cervical dislocation when signs of disease progression became evident. These signs included substantial fluctuations in body weight, diminished mobility and curiosity, respiratory distress, and/or the presence of visible or palpable tumors exceeding 15–20 mm. These indicators suggested that survival for an additional 2–3 days was unlikely. A postmortem examination was conducted to visualize the presence of tumors, assess the extent of the disease, and weigh and observe selected organs. Unless specified otherwise, autopsies consistently confirmed the presence of tumors and similar tumor loads in all euthanized mice. The detailed clinical signs and symptoms used to determine when to sacrifice mice, along with photographs illustrating tumor locations and loads observed in these cancer models, have been previously shown [41].

2.4. Diet Preparation and Composition

The six artificial diets used in this study were prepared in our laboratory by blending all solid components until they formed a homogeneous dry powder. Next, oil was incorporated into the mixture, and enough water was gradually added to achieve a soft dough consistency. This dough was air-dried for approximately 2 h; pellets were manually formed (approximately 5 g per pellet), further air-dried for an additional 24–48 h, and then stored at room temperature until required. Table 2 shows the composition of the diets employed in our study.
Casein (bovine casein 27607) was obtained from Acros Organics (Waltham, MA, USA). Sucrose and corn oil were purchased from a local market (MAS Supermarket, Seville, Spain). Cellulose and corn starch were bought from Farmusal (local pharmacy, Granada, Spain). Choline bitartrate (450225000) and tert-butylhydroquinone (150822500) were purchased from Thermo Scientific Acros Organics (Waltham, MA, USA). The dry diets contained 1% Vitamin Mix (AIN Vitamin Mixture 76, MP Biomedical, Seven Hills, Australia). A total of 100 g of the dry diets contained (mg) thiamine hydrochloride (0.6), riboflavin (0.6), pyridoxine hydrochloride (0.7), nicotinic acid (3), d-calcium pantothenate (1.6), folic acid (0.2), d-biotin (0.02), cyanocobalamin (0.001), retinyl palmitate premix (250,000 IU/g) (1.6), DL-α-tocopherol acetate (250 IU/g) (20), cholecalciferol (400,000 IU/g) (0.25), and menaquinone (0.005). A total of 1g of Vitamin Mix contained 0.9729 g of sucrose. Our Mineral Mix contained potassium phosphate monobasic (Budenheim, Budenheim, Germany), sodium fluoride (Fagron, Terrassa, Spain), iron (III) citrate (Dr. Paul Lohmann, Emmerthal, Germany), calcium carbonate (Dr. Paul Lohmann, Emmerthal, Germany), boric acid (Nutrifoods, Barcelona, Spain), potassium sulphate (Dr. Paul Lohmann, Emmerthal, Germany), potassium iodate (Nutrifoods, Barcelona, Spain), magnesium oxide (Nutrifoods, Barcelona, Spain), sodium chloride (Nutrifoods, Barcelona, Spain), silicon dioxide (Azelis, Barcelona, Spain), potassium citrate monohydrate (Nutrifoods, Barcelona, Spain), ammonium molybdate (Quality Chemicals S.L., Barcelona, Spain), chromium (III) chloride hexahydrate (Cambridge Commodities, Ely, UK), Nickel (II) carbonate hydroxide tetrahydrate (Sigma-Aldrich, Darmstadt, Germany), ammonium metavanadate (Sigma-Aldrich, Darmstadt, Germany), and lithium chloride (Sigma-Aldrich, Darmstadt, Germany). Our experimental diets (Table 2) also contained sodium selenate (Quality Chemicals S.L., Barcelona, Spain), manganese carbonate (Dr. Paul Lohmann, Emmerthal, Germany), basic copper carbonate (Dr. Paul Lohmann, Emmerthal, Germany), and/or basic zinc carbonate (Fagron, Terrassa, Spain). The ssniff diet was employed as a standard control diet (SM R/M-S E, 10 mm; V1724-000). This diet comprises 21% protein, 7% fat, 4% fiber, 6.2% ash, 33.3% starch, and 4.6% sugar. Specific components of the ssniff diet and their percentages, shown in brackets, are as follows: lysine (1.66), methionine (0.91), cystine (0.38), threonine (0.76), tryptophan (0.26), arginine (1.27), histidine (0.51), valine (0.98), isoleucine (0.89), leucine (1.57), phenylalanine (0.99), glycine (0.88), tyrosine (0.70), glutamic acid (4.38), aspartic acid (1.99), proline (1.41), serine (1.09), alanine (0.96), vitamin A (2500 IU), vitamin D3 (150 IU), vitamin E (0.0135), vitamin K (0.008), thiamine (0.0085), riboflavin (0.0032), pyridoxine (0.0031), cobalamin (0.000015), nicotinic acid (0.014), pantothenic acid (0.0059), folic acid (0.001), biotin (0.000069), choline chloride (0.337), ferrous sulphate monohydrate (0.01), zinc sulphate monohydrate (0.005), manganous-(II)-sulphate monohydrate (0.003), copper-(II)-sulfate pentahydrate (0.0005), sodium selenate (0.00001), and calcium iodate anhydrous (0.0002).

2.5. Statistical Analysis

Results are presented as mean ± standard error of the mean (SEM). Statistical analysis was conducted using GraphPad Prism (Boston, MA, USA) version 7.0 software. The Kaplan–Meier survival curve was subjected to statistical analysis using the Gehan–Breslow–Wilcoxon (GBW) test. A p value > 0.05 is considered not statistically significant and is not denoted by any symbol. A p value < 0.05 is considered statistically significant and is indicated with an asterisk (*), <0.01 with two asterisks (**), and <0.001 with three asterisks (***).

3. Results

3.1. A Diet Lacking Selenium, but Not Zinc, Copper, or Manganese, Induces Anticancer Activity in Mice with Metastatic Ovarian Cancer

To evaluate whether the dietary deprivation of selenium, zinc, copper, and manganese induces anticancer activity in mice with metastatic cancers, we employed an ovarian cancer model. The model was established by inoculating murine ID8 Trp53−/− ovarian cancer cells into the peritoneal cavity of female C57BL/6JRj mice. Treatments started 15 days after the inoculation of the cancer cells. The positive control, cisplatin (5 mg/kg), was administered intraperitoneally once a week for four weeks. We used a standard rodent diet (“Normal diet”) for the control group. We prepared six diets from scratch: a control diet that contained normal levels of selenium, zinc, copper, and manganese (control, C), and five diets that lacked selenium (C-Se), zinc (C-Zn), copper (C-Cu), manganese (C-Mn), or the four micronutrients (C-SZCM) (see Table 2). Mice treated with cisplatin were fed the standard rodent diet.
As presented in Table 3 and Figure 1a, the selenium-free diet enhanced the survival of mice with metastatic ovarian cancer. Mice fed the standard rodent diet lived 52.5 ± 1.6 days, mice fed the control diet prepared from scratch lived 60.7 ± 2.2 days, while mice fed the selenium-free diet lived 84.3 ± 13.7 days. Eliminating selenium from the diet improved mice survival by over 3 weeks (23.6 days). Mice fed our control diet prepared from scratch lived approximately 8 days longer than those receiving the standard rodent diet. Since our control diet contained casein, a protein with low levels of the sulfur amino acids (AAs) methionine and cysteine, the increased survival might be attributed to the deficiency in these AAs [42]. Mice treated with diets lacking zinc, copper, or manganese had slightly shorter survival times (non-statistically significant) compared to those fed the control diet. The mean ± SEM survival time was 58.5 ± 1.3 days for mice fed diet C-Zn, 57.7 ± 1.6 days for mice fed diet C-Cu, and 58.7 ± 1.2 days for mice fed diet C-Mn. Mice fed diet C-SZCM exhibited a moderate increase (non-statistically significant) in survival (67.3 ± 6.0 days). Cisplatin-treated mice demonstrated the highest survival rate (>96.8 ± 19.0 days). One mouse treated with cisplatin was apparently cured; it was sacrificed on day 200 without showing any sign of cancer or tumors on autopsy. Cisplatin administration into the peritoneal cavity may partially account for its significant anticancer activity because the ovarian cancer cells were also inoculated in the same place. All artificial diets were well tolerated, with no significant changes in body weights (Figure 1b). The weight gain observed in some groups prior to sacrifice can be attributed to ascitic tumor growth and the characteristic intraperitoneal fluid accumulation in this model.
We next employed this ovarian cancer model to assess the anticancer efficacy of a diet lacking selenium in combination with cisplatin. Mice survival (mean ± SEM) was 58.2 ± 1.4 days in mice fed the C diet (control diet prepared from scratch), 63.8 ± 1.5 days in mice fed the C-Se diet (selenium-free diet), 83.5 ± 3.1 days in mice receiving the C diet and cisplatin, and 84.3 ± 5.0 days in mice receiving the C-Se diet and cisplatin. The combination of cisplatin and the selenium-free diet did not significantly improve mice survival. In this second experiment, none of the animals receiving the selenium-free diet had a major improvement in survival. Table 4 and Figure 2a show the survival time of all mice with metastatic ovarian cancer treated with the selenium-free diet (obtained from the two independent experiments carried out in this model). Eliminating selenium from the diet significantly increased mice survival by 14.7 days. The diet was very well tolerated, and no significant weight losses were observed (Figure 2b).

3.2. A Diet Lacking Selenium Induces Anticancer Activity in Mice with Metastasic Colon Cancer

To confirm the efficacy of the selenium-free diet in mice with other metastatic cancers, we used a metastatic colon cancer model. Treatments were initiated four days after the inoculation of CT26.WT cells into the tail vein of immunocompetent female BALB/cAnNRj mice. Capecitabine (450 mg/kg/day), a first-line drug for metastatic colon cancer, served as a positive control. Mice on the standard rodent diet lived 30.0 ± 1.5 days, and those on the control diet lived 31.0 ± 1.4 days. The selenium-free diet extended survival to 38.9 ± 3.8 days, and capecitabine (mixed in the standard rodent diet) treatment resulted in 41.8 ± 2.7 days of survival (Table 5, Figure 3a). The selenium-free diet was very well tolerated and did not induce significant weight loss in the animals; however, moderate weight loss was observed in the capecitabine group (Figure 3b). Mice administered capecitabine also exhibited reductions in spontaneous motor activity, which reversed after the completion of each treatment.

3.3. A Diet Lacking Selenium Induces Anticancer Activity in Mice with Metastasic Triple-Negative Breast Cancer

We used a murine metastatic triple-negative breast cancer model to further validate the anticancer activity of the selenium-free diet. This model was established by inoculating murine 4T1 cells in the tail vein of female BALB/cAnNRj mice. Treatments started 4 days after the injection of the cells. The positive control cisplatin (5 mg/kg) was administered intraperitoneally once a week for 4 weeks. Mice on the control diet lived 28.3 ± 2.2 days, while those on the selenium-free diet lived 36.9 ± 6.9 days. Cisplatin treatment resulted in 39.0 ± 4.7 days of survival (Table 6, Figure 4a). The diet lacking selenium was very well tolerated, and no weight loss was observed (Figure 4b). In contrast, moderate weight loss was observed in most mice treated with cisplatin, and two mice treated with this drug died on day 8 because of cisplatin toxicity. These two mice started to lose weight and developed other signs of toxicity (e.g., abnormal gait/posture, pale ears, lack of curiosity, and reluctance to move) after the first cisplatin injection (these two mice are not included in Table 6 but are shown in Figure 4a).

4. Discussion

It is widely accepted that patients with non-resectable metastatic cancers must be treated with drugs. The objective of this work is to evaluate a new therapeutic strategy for the treatment of metastatic cancers that does not rely on the use of drugs. Instead of administering cytotoxic molecules to kill cancer cells, our strategy consists of temporarily eliminating dietary components that cancer cells may need to survive. Selenium, zinc, copper, and manganese are essential components of antioxidant enzymes involved in the elimination of reactive oxygen species (ROS). Since cancer cells produce high levels of ROS and ROS accumulation induces cell death, cancer cells may be vulnerable to diets lacking these micronutrients. In this work, we prepared several artificial diets containing normal carbohydrate, protein, and lipid levels but lacking selenium, zinc, copper, or manganese and evaluated their anticancer activity in mice with metastatic cancers.
To test the hypothesis that dietary depletion of these micronutrients can induce anticancer activity in mice with metastatic cancer, we initially used an ovarian cancer model. Our initial experiment showed that the selenium-free diet enhanced the mean survival of mice with disseminated ovarian cancer, whereas diets lacking zinc, copper, or manganese did not exhibit anticancer activity (Table 3, Figure 1). The diet deficient in all four micronutrients (C-SZCM) showed less anticancer activity compared to the diet lacking selenium only (Table 3). Although previous studies indicate that zinc, copper, and manganese deficiencies can increase ROS levels and induce oxidative stress [43,44], our diets lacking zinc, copper, or manganese failed to exhibit anticancer activity. The accumulation of H2O2 might explain why selenium restriction induces anticancer activity, in contrast to deficiencies in zinc, copper, and manganese. Cancer cells are known to produce high levels of H2O2 [4] and the cellular accumulation of H2O2 can selectively kill cancer cells [5,45]. Copper, zinc, and manganese are essential components of SOD enzymes, which convert superoxide anions into H2O2. Later, selenium-dependent enzymes (glutathione peroxidases and thioredoxin reductases) and selenium-independent enzymes (catalase and peroxiredoxins) can convert H2O2 into water [5,7]. Consequently, diets lacking copper, zinc, or manganese would reduce H2O2 production, while diets lacking selenium would result in H2O2 accumulation. The diet lacking all four minerals would reduce the activity of SOD enzymes, thereby decreasing the conversion of superoxide anions into H2O2. Simultaneously, selenium deficiency would reduce the function of selenium-dependent enzymes responsible for eliminating H2O2, which would lead to an accumulation of H2O2 that is produced by other sources that do not require SOD activity. The net effect would depend on the balance between reduced H2O2 production (due to copper, zinc, and manganese deficiencies) and impaired H2O2 detoxification (due to selenium deficiency). The mild survival improvements observed in mice fed the diet lacking the four minerals suggest that the selenium deficiency-driven H2O2 accumulation might still be high enough to kill a small percentage of cancer cells and increase the mean survival of the mice. Accordingly, previous data from a non-metastatic xenograft model of glioblastoma showed that selenium deficiency significantly reduced circulating selenium levels and increased the anticancer activity of ascorbate by inducing H2O2 accumulation [46].
We conducted an additional experiment to confirm that the selenium-free diet improved the survival of mice with ovarian cancer. Although we observed improved survival rates compared to untreated mice, mice treated with the standard anticancer agent cisplatin exhibited longer survival benefits (Table 3 and Table 4, Figure 1 and Figure 2). The high efficacy of cisplatin might be partially attributed to the direct injection of this drug into the region where ovarian cancer cells were inoculated in mice. The combination of cisplatin with the selenium-free diet did not significantly enhance the survival observed with cisplatin alone. These data suggest that the concomitant use of cisplatin therapy and a diet lacking selenium would not result in significant improvements in the survival of patients with ovarian cancer, at least under our experimental conditions.
To further validate the anticancer activity of the selenium-free diet, we employed a metastatic model of colon cancer, established by inoculating murine colon cancer cells into the tail vein of immunocompetent BALB/cAnNRj mice. Mice fed the selenium-free diet lived approximately 9 days longer than mice fed a standard rodent diet, which was 3 days shorter than the survival achieved in the group of mice treated with capecitabine (Table 5, Figure 3). Capecitabine is a first-line anticancer drug widely used for treating people with metastatic colon cancer. Notably, unlike mice treated with capecitabine, those fed the selenium-free diet did not exhibit any signs of toxicity.
Lastly, we assessed the anticancer activity of the selenium-free diet in a metastatic model of triple-negative breast cancer, established by injecting 4T1 murine cancer cells into the tail vein of immunocompetent BALB/cAnNRj mice. Our findings revealed enhanced mean survival in mice treated with the selenium-deficient diet compared to the control group, with efficacy similar to that observed in the cisplatin-treated group. The selenium-free diet was well tolerated, with no observed weight loss (Figure 4b). In contrast, cisplatin induced moderate weight loss in most mice, and two mice treated with this drug died on day 8 due to cisplatin toxicity (Table 6, Figure 4).
While our study is the first to investigate the effects of dietary selenium removal in mice with metastatic cancers, earlier in vivo research has shown that selenium deficiency can prevent cancer formation and delay the growth of localized tumors in mice. Felix et al. [47] found that all BALB/c mice maintained on a torula-based low-selenium diet (5–8 µg of selenium/kg) were completely resistant to pristane induction of peritoneal plasmacytomas. In contrast, 42.3% of control mice on a selenium-adequate torula diet (300 µg of selenium/kg) and 37.5% of control mice fed standard Purina chow (440 µg of selenium/kg) developed peritoneal plasmacytomas [47]. A diet lacking selenium also reduced tumor incidence in TGFα/c-Myc transgenic mice; these mice have disrupted redox homeostasis and develop liver cancer by 6 months of age [48]. Selenium dietary restriction also induced anticancer activity and improved ascorbate efficacy in a mouse xenograft model of glioblastoma [46]. Selenium dietary restriction has also been shown to alleviate leukocytosis, decrease leukemic burden, and significantly prolong leukemia-free survival in xenograft models of acute myeloid leukemia (AML). Notably, these effects occurred with minimal impact on normal hematopoiesis [49].
Consistent with our findings, earlier studies have shown that removing copper and zinc from the diet does not exhibit anticancer activity. In a study involving male Sprague-Dawley rats fed copper-deficient and -non-deficient diets (7 days before cancer cell implantation), it was concluded that copper deficiency had no impact on tumor growth, vascular density, or ultrastructural tumor characteristics [50]. Additionally, dietary zinc deficiency was found to increase the incidence and reduce the lag time for the induction of esophageal tumors in rats by methylbenzylnitrosamine [51]. Although diets lacking copper have not shown anticancer activity, copper chelators have shown antitumor potential due to their ability to disrupt copper homeostasis in cancer cells. By binding to and removing excess copper, these chelators can inhibit tumor growth and metastasis [52,53].
It is worth noting that our selenium-free diet improved mean survival in mice with three distinct types of metastatic cancers (ovarian, colon, and breast cancer) without causing toxicity in the animals. Triple-negative breast cancer (TNBC) is known to be a particularly aggressive form of breast cancer [54,55], and our metastatic TNBC mouse model is particularly challenging. Indeed, we previously observed that two drugs commonly used to treat women with metastatic TNBC, capecitabine and doxorubicin, were virtually ineffective in our model [41]. While cisplatin enhanced mice survival in this model, two mice died on day 8 due to cisplatin toxicity (Table 6, Figure 4). Given that the only difference between our control diet and the selenium-free diet is the presence or absence of a small amount of selenium (Table 2), we can conclude that the dietary elimination of selenium for several weeks can improve the survival rates of mice with different types of metastatic cancers. Although our artificial diets were formulated without Se, Zn, Cu, and/or Mn, the final levels of these micronutrients in the diets given to the animals have not been analyzed. Since we used some dietary components that are not chemically defined (e.g., casein), we cannot assure that the final amount of Se in our C-Se diet is exactly 0%.
The lack of toxicity of our selenium-free diet may seem surprising, given that selenium is an essential micronutrient with crucial physiological roles. However, evidence suggests that adult individuals can tolerate selenium deficiency for extended periods. Yim et al. [56] reported that, while a selenium-free diet led to a significant decline in selenoprotein expression, mice subjected to this dietary regimen throughout their life had normal lifespans. To understand the underlying molecular mechanisms, the authors conducted systemic analyses at the levels of metabolome, transcriptome, and microRNA profiling. Their findings indicated that selenium deficiency reduced amino acid levels, elevated mononucleotides, altered metabolism, and activated signaling pathways associated with longevity-related nutrient sensing. These activated pathways appear to protect mice against the absence of dietary selenium. Furthermore, the study confirmed the known priority for selenium supply in different organs; the liver showed a rapid depletion of selenoproteins in response to selenium deficiency, whereas brain selenoprotein expression remained largely unchanged [56]. In humans, 99 days on a low-selenium diet did not change the overall health of a small group of men [57].
Several mechanisms may contribute to explaining the selective anticancer activity of selenium deficiency in vivo. As previously mentioned, selenium plays a critical role in the detoxification of H2O2. Since cancer cells produce substantial amounts of H2O2 [4,5], they may require higher selenium levels than normal cells to prevent the accumulation of cytotoxic H2O2 concentrations. Consistently, a radioactive form of dietary selenium compound (selenite) was found to accumulate preferentially in tumors, a phenomenon explored as a tumor-labeling strategy in clinical settings during the 1960s [58,59]. More recently, Charalabopoulos et al. [34] conducted a study involving 80 women with breast cancer who underwent radical mastectomy. The results revealed that serum selenium levels were 42.5 ± 7.5 µg/L in breast cancer patients, compared to 67.6 ± 5.36 µg/L in an age-matched control group of healthy individuals. However, selenium concentrations in neoplastic tissues were 2660 ± 210 mg/g tissue, whereas those in adjacent non-neoplastic tissues were 680 ± 110 mg/g tissue (p < 0.001). These data demonstrate that, despite lower serum selenium levels in women with breast cancer compared to healthy individuals, selenium concentrations in breast cancer tissues were significantly higher than in adjacent non-cancerous tissues. Carlisle et al. [60] demonstrated that selenophosphate synthetase 2 (SEPHS2), an enzyme in the selenocysteine biosynthesis pathway (essential for the production of all selenoproteins), was vital for the survival of many cancer cell types but not for normal cells. Non-transformed MCF10A cells lacking SEPHS2 were able to maintain their growth rate for 28 days despite losing SEPHS2 and selenoprotein expression capabilities [60]. The authors suggested that, under basal conditions, normal cells neither require SEPHS2 nor selenoprotein production for their survival and proliferation. They also observed that cancer cells can activate the cystine/glutamate antiporter SLC7A11 to promote selenium uptake [60]. Eagle et al. [49] reported that SEPHS2 regulates selenoprotein production in AML, and its suppression through diet renders these leukemia cells susceptible to oxidative stress without harming hematopoiesis [49]. Reduced amino acid levels caused by selenium-free diets may also contribute to explaining the selective anticancer activity of selenium deficiency in vivo. Yim et al. [56] found that selenium deficiency significantly reduced the levels of seven amino acids: asparagine, leucine, lysine, methionine, phenylalanine, serine, and threonine. Amino acid restriction can induce selective killing of cancer cells in vitro and improve the survival rates of mice with several metastatic cancer types, as reviewed in [61].
Although our selenium-free diet enhanced the survival of mice with several metastatic cancers without causing toxicity, it is important to note that all mice eventually died. In our previous studies [41,42,62,63], we found that several artificial diets with modified amino acid and lipid levels led to significant improvements in the survival rates of mice with several metastatic cancers. Some diets even outperformed standard anticancer therapies and cured a small percentage of mice [41,42,62,63]. Currently, we are evaluating the anticancer activity of a variety of selenium-free diets with altered amino acid and lipid levels in animal models of metastasis. We are also testing one of these selenium-free diets as monotherapy in patients with advanced metastatic cancers. Their blood samples are being analyzed at various time points to measure various parameters, including selenium levels. Although these artificial diets could be clinically useful as monotherapy, we are also testing their efficacy in mice in combination with standard drugs used in cancer patients.

5. Conclusions

Our findings demonstrate for the first time that a selenium-free diet, but not diets lacking zinc, copper, or manganese, enhances the mean survival rates of mice with metastatic cancers, without causing toxicity in the animals. These results underscore the potential of using selenium-free diets in the treatment of metastatic cancers. Further research is warranted to explore potential mechanisms and optimal dietary strategies to maximize the anticancer efficacy of selenium-free diets, both as a monotherapy and in combination with existing cancer therapies.

Author Contributions

Conceptualization, M.L.-L.; Data curation, P.D.-O., J.M.C.-M., J.J.J.-A., E.G.-M., E.B.-M. and M.L.-L.; Formal analysis, P.D.-O., J.M.C.-M., J.J.J.-A., E.G.-M., E.B.-M. and M.L.-L.; Funding acquisition, M.L.-L.; Investigation, P.D.-O., J.M.C.-M., J.J.J.-A., E.G.-M., V.J.-G., E.B.-M. and M.L.-L.; Methodology, P.D.-O., J.M.C.-M., J.J.J.-A., E.G.-M., E.B.-M. and M.L.-L.; Project administration, M.L.-L.; Resources, M.L.-L.; Supervision, M.L.-L.; Validation, P.D.-O., J.M.C.-M., J.J.J.-A., E.G.-M., E.B.-M. and M.L.-L.; Visualization, P.D.-O., J.M.C.-M., J.J.J.-A., V.J.-G., E.B.-M. and M.L.-L.; Writing—original draft, P.D.-O., E.B.-M. and M.L.-L.; Writing—review and editing, P.D.-O. and M.L.-L. All authors have read and agreed to the published version of the manuscript.

Funding

This research was funded by AMINOVITA, S.L. (PRJ201803388). Additional support was given by Junta de Andalucía (grant numbers 2017/CTS-657; 2019/CTS-657; 2021/CTS-657) and the University of Seville through the “VI Plan Propio de Investigación y Transferencia” (grant numbers VIPPIT-2019-I.5, VIPPIT-2020-I.5, VIPPIT-2021-I.5, and VIIPPIT-2023-I.3).

Institutional Review Board Statement

The experiments were approved by the Animal Ethics Committee of the University of Seville (CEEA-US2018-6/2 and CEEA-US2019-20) and Junta de Andalucía (15/05/2018/090 and 13/11/2020/131).

Informed Consent Statement

Not applicable.

Data Availability Statement

Data are contained within the article.

Acknowledgments

We thank biology services of CITIUS-University of Seville for the cryopreservation of cell lines. We are especially grateful to AMINOVITA, S.L., for supporting our investigation. J.J.J.-A. thanks Ministerio de Universidades (Spain) for a predoctoral FPU fellowship, and E.G.-M. thanks the University of Seville for a predoctoral fellowship and postdoctoral fellowship.

Conflicts of Interest

J.M. Calderón-Montaño, V. Jiménez-González, and M. López-Lázaro have shares in AMINOVITA, S.L. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript; or in the decision to publish the results.

References

  1. Siegel, R.L.; Giaquinto, A.N.; Jemal, A. Cancer Statistics, 2024. CA Cancer J. Clin. 2024, 74, 12–49. [Google Scholar] [CrossRef] [PubMed]
  2. López-Lázaro, M. Selective Amino Acid Restriction Therapy (SAART): A Non-Pharmacological Strategy against All Types of Cancer Cells. Oncoscience 2015, 2, 857–866. [Google Scholar] [CrossRef] [PubMed]
  3. López-Lázaro, M. Two Preclinical Tests to Evaluate Anticancer Activity and to Help Validate Drug Candidates for Clinical Trials. Oncoscience 2015, 2, 91–98. [Google Scholar] [CrossRef]
  4. Szatrowski, T.P.; Nathan, C.F. Production of Large Amounts of Hydrogen Peroxide by Human Tumor Cells. Cancer Res. 1991, 51, 794–798. [Google Scholar] [PubMed]
  5. López-Lázaro, M. Dual Role of Hydrogen Peroxide in Cancer: Possible Relevance to Cancer Chemoprevention and Therapy. Cancer Lett. 2007, 252, 1–8. [Google Scholar] [CrossRef] [PubMed]
  6. Martin-Cordero, C.; Leon-Gonzalez, A.J.; Calderon-Montano, J.M.; Burgos-Moron, E.; Lopez-Lazaro, M. Pro-Oxidant Natural Products as Anticancer Agents. Curr. Drug Targets 2012, 13, 1006–1028. [Google Scholar] [CrossRef] [PubMed]
  7. López-Lázaro, M. Excessive Superoxide Anion Generation Plays a Key Role in Carcinogenesis. Int. J. Cancer 2007, 120, 1378–1380. [Google Scholar] [CrossRef] [PubMed]
  8. Ganichkin, O.M.; Xu, X.-M.; Carlson, B.A.; Mix, H.; Hatfield, D.L.; Gladyshev, V.N.; Wahl, M.C. Structure and Catalytic Mechanism of Eukaryotic Selenocysteine Synthase. J. Biol. Chem. 2008, 283, 5849–5865. [Google Scholar] [CrossRef] [PubMed]
  9. Rayman, M.P. The Importance of Selenium to Human Health. Lancet 2000, 356, 233–241. [Google Scholar] [CrossRef] [PubMed]
  10. Rotruck, J.T.; Pope, A.L.; Ganther, H.E.; Swanson, A.B.; Hafeman, D.G.; Hoekstra, W.G. Selenium: Biochemical Role as a Component of Glutathione Peroxidase. Science 1973, 179, 588–590. [Google Scholar] [CrossRef]
  11. Hatfield, D.L.; Tsuji, P.A.; Carlson, B.A.; Gladyshev, V.N. Selenium and Selenocysteine: Roles in Cancer, Health, and Development. Trends Biochem. Sci. 2014, 39, 112–120. [Google Scholar] [CrossRef] [PubMed]
  12. Flohé, L.; Toppo, S.; Orian, L. The Glutathione Peroxidase Family: Discoveries and Mechanism. Free Radic. Biol. Med. 2022, 187, 113–122. [Google Scholar] [CrossRef] [PubMed]
  13. Terrin, G.; Berni Canani, R.; Di Chiara, M.; Pietravalle, A.; Aleandri, V.; Conte, F.; De Curtis, M. Zinc in Early Life: A Key Element in the Fetus and Preterm Neonate. Nutrients 2015, 7, 10427–10446. [Google Scholar] [CrossRef] [PubMed]
  14. King, J.C. Zinc: An Essential but Elusive Nutrient. Am. J. Clin. Nutr. 2011, 94, 679S–684S. [Google Scholar] [CrossRef] [PubMed]
  15. Chasapis, C.T.; Ntoupa, P.-S.A.; Spiliopoulou, C.A.; Stefanidou, M.E. Recent Aspects of the Effects of Zinc on Human Health. Arch. Toxicol. 2020, 94, 1443–1460. [Google Scholar] [CrossRef] [PubMed]
  16. Linder, M.C.; Hazegh-Azam, M. Copper Biochemistry and Molecular Biology. Am. J. Clin. Nutr. 1996, 63, 797S–811S. [Google Scholar] [CrossRef] [PubMed]
  17. Prohaska, J.R. Impact of Copper Limitation on Expression and Function of Multicopper Oxidases (Ferroxidases). Adv. Nutr. 2011, 2, 89–95. [Google Scholar] [CrossRef] [PubMed]
  18. Br, S. Ferroptosis Turns 10: Emerging Mechanisms, Physiological Functions, and Therapeutic Applications. Cell 2022, 185, 2401–2421. [Google Scholar] [CrossRef]
  19. Tang, D.; Kroemer, G.; Kang, R. Targeting Cuproplasia and Cuproptosis in Cancer. Nat. Rev. Clin. Oncol. 2024, 21, 370–388. [Google Scholar] [CrossRef] [PubMed]
  20. Aschner, J.L.; Aschner, M. Nutritional Aspects of Manganese Homeostasis. Mol. Aspects Med. 2005, 26, 353–362. [Google Scholar] [CrossRef] [PubMed]
  21. Minerals. Available online: https://lpi.oregonstate.edu/mic/minerals (accessed on 2 July 2024).
  22. Radomska, D.; Czarnomysy, R.; Radomski, D.; Bielawska, A.; Bielawski, K. Selenium as a Bioactive Micronutrient in the Human Diet and Its Cancer Chemopreventive Activity. Nutrients 2021, 13, 1649. [Google Scholar] [CrossRef] [PubMed]
  23. Razaghi, A.; Poorebrahim, M.; Sarhan, D.; Björnstedt, M. Selenium Stimulates the Antitumour Immunity: Insights to Future Research. Eur. J. Cancer 2021, 155, 256–267. [Google Scholar] [CrossRef] [PubMed]
  24. Golara, A.; Kozłowski, M.; Guzik, P.; Kwiatkowski, S.; Cymbaluk-Płoska, A. The Role of Selenium and Manganese in the Formation, Diagnosis and Treatment of Cervical, Endometrial and Ovarian Cancer. Int. J. Mol. Sci. 2023, 24, 10887. [Google Scholar] [CrossRef] [PubMed]
  25. Skrajnowska, D.; Bobrowska-Korczak, B. Role of Zinc in Immune System and Anti-Cancer Defense Mechanisms. Nutrients 2019, 11, 2273. [Google Scholar] [CrossRef] [PubMed]
  26. Bendellaa, M.; Lelièvre, P.; Coll, J.-L.; Sancey, L.; Deniaud, A.; Busser, B. Roles of Zinc in Cancers: From Altered Metabolism to Therapeutic Applications. Int. J. Cancer 2024, 154, 7–20. [Google Scholar] [CrossRef] [PubMed]
  27. Ge, E.J.; Bush, A.I.; Casini, A.; Cobine, P.A.; Cross, J.R.; DeNicola, G.M.; Dou, Q.P.; Franz, K.J.; Gohil, V.M.; Gupta, S.; et al. Connecting Copper and Cancer: From Transition Metal Signalling to Metalloplasia. Nat. Rev. Cancer 2022, 22, 102–113. [Google Scholar] [CrossRef] [PubMed]
  28. Shanbhag, V.C.; Gudekar, N.; Jasmer, K.; Papageorgiou, C.; Singh, K.; Petris, M.J. Copper Metabolism as a Unique Vulnerability in Cancer. Biochim. Biophys. Acta Mol. Cell Res. 2021, 1868, 118893. [Google Scholar] [CrossRef] [PubMed]
  29. Lelièvre, P.; Sancey, L.; Coll, J.-L.; Deniaud, A.; Busser, B. The Multifaceted Roles of Copper in Cancer: A Trace Metal Element with Dysregulated Metabolism, but Also a Target or a Bullet for Therapy. Cancers 2020, 12, 3594. [Google Scholar] [CrossRef] [PubMed]
  30. Lv, M.; Chen, M.; Zhang, R.; Zhang, W.; Wang, C.; Zhang, Y.; Wei, X.; Guan, Y.; Liu, J.; Feng, K.; et al. Manganese Is Critical for Antitumor Immune Responses via cGAS-STING and Improves the Efficacy of Clinical Immunotherapy. Cell Res. 2020, 30, 966–979. [Google Scholar] [CrossRef] [PubMed]
  31. Saleh, S.A.K.; Adly, H.M.; Abdelkhaliq, A.A.; Nassir, A.M. Serum Levels of Selenium, Zinc, Copper, Manganese, and Iron in Prostate Cancer Patients. Curr. Urol. 2020, 14, 44–49. [Google Scholar] [CrossRef] [PubMed]
  32. Szwiec, M.; Marciniak, W.; Derkacz, R.; Huzarski, T.; Gronwald, J.; Cybulski, C.; Dębniak, T.; Jakubowska, A.; Lener, M.R.; Falco, M.; et al. Serum Levels of Copper and Zinc and Survival in Breast Cancer Patients. Nutrients 2024, 16, 1000. [Google Scholar] [CrossRef] [PubMed]
  33. Szwiec, M.; Marciniak, W.; Derkacz, R.; Huzarski, T.; Gronwald, J.; Cybulski, C.; Dębniak, T.; Jakubowska, A.; Lener, M.; Falco, M.; et al. Serum Selenium Level Predicts 10-Year Survival after Breast Cancer. Nutrients 2021, 13, 953. [Google Scholar] [CrossRef] [PubMed]
  34. Charalabopoulos, K.; Kotsalos, A.; Batistatou, A.; Charalabopoulos, A.; Vezyraki, P.; Peschos, D.; Kalfakakou, V.; Evangelou, A. Selenium in Serum and Neoplastic Tissue in Breast Cancer: Correlation with CEA. Br. J. Cancer 2006, 95, 674–676. [Google Scholar] [CrossRef] [PubMed]
  35. Walton, J.B.; Farquharson, M.; Mason, S.; Port, J.; Kruspig, B.; Dowson, S.; Stevenson, D.; Murphy, D.; Matzuk, M.; Kim, J.; et al. CRISPR/Cas9-Derived Models of Ovarian High Grade Serous Carcinoma Targeting Brca1, Pten and Nf1, and Correlation with Platinum Sensitivity. Sci. Rep. 2017, 7, 16827. [Google Scholar] [CrossRef] [PubMed]
  36. Corbett, T.H.; Griswold, D.P.; Roberts, B.J.; Peckham, J.C.; Schabel, F.M. Tumor Induction Relationships in Development of Transplantable Cancers of the Colon in Mice for Chemotherapy Assays, with a Note on Carcinogen Structure. Cancer Res. 1975, 35, 2434–2439. [Google Scholar] [PubMed]
  37. Wang, L.; Hu, X.; Xu, Y.; Liu, Z. Arsenic Trioxide Inhibits Lung Metastasis of Mouse Colon Cancer via Reducing the Infiltration of Regulatory T Cells. Tumour Biol. J. Int. Soc. Oncodev. Biol. Med. 2016, 37, 15165–15173. [Google Scholar] [CrossRef] [PubMed]
  38. Kolinsky, K.; Shen, B.-Q.; Zhang, Y.-E.; Kohles, J.; Dugan, U.; Zioncheck, T.F.; Heimbrook, D.; Packman, K.; Higgins, B. In Vivo Activity of Novel Capecitabine Regimens Alone and with Bevacizumab and Oxaliplatin in Colorectal Cancer Xenograft Models. Mol. Cancer Ther. 2009, 8, 75–82. [Google Scholar] [CrossRef] [PubMed]
  39. Aslakson, C.J.; Miller, F.R. Selective Events in the Metastatic Process Defined by Analysis of the Sequential Dissemination of Subpopulations of a Mouse Mammary Tumor. Cancer Res. 1992, 52, 1399–1405. [Google Scholar] [PubMed]
  40. Liu, Y.; Wang, L.; Liu, J.; Xie, X.; Hu, H.; Luo, F. Anticancer Effects of ACT001 via NF-κB Suppression in Murine Triple-Negative Breast Cancer Cell Line 4T1. Cancer Manag. Res. 2020, 12, 5131–5139. [Google Scholar] [CrossRef] [PubMed]
  41. Guillén-Mancina, E.; Jiménez-Alonso, J.J.; Calderón-Montaño, J.M.; Jiménez-González, V.; Díaz-Ortega, P.; Burgos-Morón, E.; López-Lázaro, M. Artificial Diets with Selective Restriction of Amino Acids and Very Low Levels of Lipids Induce Anticancer Activity in Mice with Metastatic Triple-Negative Breast Cancer. Cancers 2023, 15, 1540. [Google Scholar] [CrossRef] [PubMed]
  42. Jiménez-Alonso, J.J.; Guillén-Mancina, E.; Calderón-Montaño, J.M.; Jiménez-González, V.; Díaz-Ortega, P.; Burgos-Morón, E.; López-Lázaro, M. Artificial Diets with Altered Levels of Sulfur Amino Acids Induce Anticancer Activity in Mice with Metastatic Colon Cancer, Ovarian Cancer and Renal Cell Carcinoma. Int. J. Mol. Sci. 2023, 24, 4587. [Google Scholar] [CrossRef] [PubMed]
  43. Prohaska, J.R.; Brokate, B. Lower Copper, Zinc-Superoxide Dismutase Protein but Not mRNA in Organs of Copper-Deficient Rats. Arch. Biochem. Biophys. 2001, 393, 170–176. [Google Scholar] [CrossRef] [PubMed]
  44. Bruno, R.S.; Song, Y.; Leonard, S.W.; Mustacich, D.J.; Taylor, A.W.; Traber, M.G.; Ho, E. Dietary Zinc Restriction in Rats Alters Antioxidant Status and Increases Plasma F2 Isoprostanes. J. Nutr. Biochem. 2007, 18, 509–518. [Google Scholar] [CrossRef] [PubMed]
  45. López-Lázaro, M.; Calderón-Montaño, J.M.; Burgos-Morón, E.; Austin, C.A. Green Tea Constituents (-)-Epigallocatechin-3-Gallate (EGCG) and Gallic Acid Induce Topoisomerase I- and Topoisomerase II-DNA Complexes in Cells Mediated by Pyrogallol-Induced Hydrogen Peroxide. Mutagenesis 2011, 26, 489–498. [Google Scholar] [CrossRef] [PubMed]
  46. Jankowski, C.S.R.; Rabinowitz, J.D. Selenium Modulates Cancer Cell Response to Pharmacologic Ascorbate. Cancer Res. 2022, 82, 3486–3498. [Google Scholar] [CrossRef]
  47. Felix, K.; Gerstmeier, S.; Kyriakopoulos, A.; Howard, O.M.Z.; Dong, H.-F.; Eckhaus, M.; Behne, D.; Bornkamm, G.W.; Janz, S. Selenium Deficiency Abrogates Inflammation-Dependent Plasma Cell Tumors in Mice. Cancer Res. 2004, 64, 2910–2917. [Google Scholar] [CrossRef] [PubMed]
  48. Novoselov, S.V.; Calvisi, D.F.; Labunskyy, V.M.; Factor, V.M.; Carlson, B.A.; Fomenko, D.E.; Moustafa, M.E.; Hatfield, D.L.; Gladyshev, V.N. Selenoprotein Deficiency and High Levels of Selenium Compounds Can Effectively Inhibit Hepatocarcinogenesis in Transgenic Mice. Oncogene 2005, 24, 8003–8011. [Google Scholar] [CrossRef] [PubMed]
  49. Eagle, K.; Jiang, Y.; Shi, X.; Li, M.; Obholzer, N.P.; Hu, T.; Perez, M.W.; Koren, J.V.; Kitano, A.; Yi, J.S.; et al. An Oncogenic Enhancer Encodes Selective Selenium Dependency in AML. Cell Stem Cell 2022, 29, 386–399.e7. [Google Scholar] [CrossRef]
  50. Schuschke, D.A.; Reed, M.W.; Saari, J.T.; Olson, M.D.; Ackermann, D.M.; Miller, F.N. Short-Term Dietary Copper Deficiency Does Not Inhibit Angiogenesis in Tumours Implanted in Striated Muscle. Br. J. Cancer 1992, 66, 1059–1064. [Google Scholar] [CrossRef]
  51. Fong, L.Y.; Sivak, A.; Newberne, P.M. Zinc Deficiency and Methylbenzylnitrosamine-Induced Esophageal Cancer in Rats. J. Natl. Cancer Inst. 1978, 61, 145–150. [Google Scholar] [CrossRef] [PubMed]
  52. Wang, X.; Zhou, M.; Liu, Y.; Si, Z. Cope with Copper: From Copper Linked Mechanisms to Copper-Based Clinical Cancer Therapies. Cancer Lett. 2023, 561, 216157. [Google Scholar] [CrossRef] [PubMed]
  53. Baldari, S.; Di Rocco, G.; Toietta, G. Current Biomedical Use of Copper Chelation Therapy. Int. J. Mol. Sci. 2020, 21, 1069. [Google Scholar] [CrossRef] [PubMed]
  54. Bianchini, G.; Balko, J.M.; Mayer, I.A.; Sanders, M.E.; Gianni, L. Triple-Negative Breast Cancer: Challenges and Opportunities of a Heterogeneous Disease. Nat. Rev. Clin. Oncol. 2016, 13, 674–690. [Google Scholar] [CrossRef] [PubMed]
  55. Dent, R.; Trudeau, M.; Pritchard, K.I.; Hanna, W.M.; Kahn, H.K.; Sawka, C.A.; Lickley, L.A.; Rawlinson, E.; Sun, P.; Narod, S.A. Triple-Negative Breast Cancer: Clinical Features and Patterns of Recurrence. Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res. 2007, 13, 4429–4434. [Google Scholar] [CrossRef] [PubMed]
  56. Yim, S.H.; Clish, C.B.; Gladyshev, V.N. Selenium Deficiency Is Associated with Pro-Longevity Mechanisms. Cell Rep. 2019, 27, 2785–2797.e3. [Google Scholar] [CrossRef] [PubMed]
  57. Hawkes, W.C.; Kelley, D.S.; Taylor, P.C. The Effects of Dietary Selenium on the Immune System in Healthy Men. Biol. Trace Elem. Res. 2001, 81, 189–213. [Google Scholar] [CrossRef] [PubMed]
  58. Cavalieri, R.R.; Scott, K.G.; Sairenji, E. Selenite (75Se) as a Tumor-Localizing Agent in Man. J. Nucl. Med. Off. Publ. Soc. Nucl. Med. 1966, 7, 197–208. [Google Scholar]
  59. Cavalieri, R.R.; Scott, K.G. Sodium Selenite Se 75. A More Specific Agent for Scanning Tumors. JAMA 1968, 206, 591–595. [Google Scholar] [CrossRef] [PubMed]
  60. Carlisle, A.E.; Lee, N.; Matthew-Onabanjo, A.N.; Spears, M.E.; Park, S.J.; Youkana, D.; Doshi, M.B.; Peppers, A.; Li, R.; Joseph, A.B.; et al. Selenium Detoxification Is Required for Cancer-Cell Survival. Nat. Metab. 2020, 2, 603–611. [Google Scholar] [CrossRef] [PubMed]
  61. Jiménez-Alonso, J.J.; López-Lázaro, M. Dietary Manipulation of Amino Acids for Cancer Therapy. Nutrients 2023, 15, 2879. [Google Scholar] [CrossRef] [PubMed]
  62. Jiménez-Alonso, J.J.; Guillén-Mancina, E.; Calderón-Montaño, J.M.; Jiménez-González, V.; Díaz-Ortega, P.; Burgos-Morón, E.; López-Lázaro, M. Artificial Diets Based on Selective Amino Acid Restriction versus Capecitabine in Mice with Metastatic Colon Cancer. Nutrients 2022, 14, 3378. [Google Scholar] [CrossRef] [PubMed]
  63. Calderón-Montaño, J.M.; Guillén-Mancina, E.; Jiménez-Alonso, J.J.; Jiménez-González, V.; Burgos-Morón, E.; Mate, A.; Pérez-Guerrero, M.C.; López-Lázaro, M. Manipulation of Amino Acid Levels with Artificial Diets Induces a Marked Anticancer Activity in Mice with Renal Cell Carcinoma. Int. J. Mol. Sci. 2022, 23, 16132. [Google Scholar] [CrossRef] [PubMed]
Nutrients 16 02249 g001aNutrients 16 02249 g001b
Figure 1. Anticancer activity of cisplatin and diets lacking selenium, zinc, copper, or manganese in mice with metastatic ovarian cancer (ID8 Trp53−/− murine ovarian cancer cells inoculated in peritoneal cavity of female C57BL/6JRj mice). (a) Survival of mice treated with cisplatin (intraperitoneal administration of 5 mg/kg cisplatin once a week for 4 weeks), mice fed normal standard diet, control diet prepared from scratch, and diets lacking selenium, zinc, copper, and/or manganese. (b) Body weights of mice relative to body weights at beginning of treatments (day 15). Normal diet: standard rodent diet; control: control diet prepared from scratch; C-Se: diet without selenium; C-Zn; diet without zinc; C-Cu: diet without copper; C-Mn: diet without manganese; C-SZCM: diet without selenium, zinc, copper, and manganese.
Figure 1. Anticancer activity of cisplatin and diets lacking selenium, zinc, copper, or manganese in mice with metastatic ovarian cancer (ID8 Trp53−/− murine ovarian cancer cells inoculated in peritoneal cavity of female C57BL/6JRj mice). (a) Survival of mice treated with cisplatin (intraperitoneal administration of 5 mg/kg cisplatin once a week for 4 weeks), mice fed normal standard diet, control diet prepared from scratch, and diets lacking selenium, zinc, copper, and/or manganese. (b) Body weights of mice relative to body weights at beginning of treatments (day 15). Normal diet: standard rodent diet; control: control diet prepared from scratch; C-Se: diet without selenium; C-Zn; diet without zinc; C-Cu: diet without copper; C-Mn: diet without manganese; C-SZCM: diet without selenium, zinc, copper, and manganese.
Nutrients 16 02249 g001aNutrients 16 02249 g001b
Nutrients 16 02249 g002
Figure 2. The anticancer activity of cisplatin and a diet lacking selenium in mice with metastatic ovarian cancer (stablished by inoculating ID8 Trp53−/− murine ovarian cancer cells in the peritoneal cavity of female C57BL/6JRj mice). (a) The survival of mice fed a control diet prepared from scratch (control), mice fed a diet lacking selenium (C-Se), and mice fed the control diet and treated with cisplatin (intraperitoneal administration of 5 mg/kg once a week for 4 weeks). (b) The body weights of the mice relative to their body weights at the beginning of treatments (day 15). (c) Representative photographs at the time of sacrifice of the peritoneal cavity of mice with ovarian cancer. White arrowheads point to specific tumors. The day of sacrifice is shown in brackets. Data for the control and C-Se groups are from two independent experiments (see text for details).
Figure 2. The anticancer activity of cisplatin and a diet lacking selenium in mice with metastatic ovarian cancer (stablished by inoculating ID8 Trp53−/− murine ovarian cancer cells in the peritoneal cavity of female C57BL/6JRj mice). (a) The survival of mice fed a control diet prepared from scratch (control), mice fed a diet lacking selenium (C-Se), and mice fed the control diet and treated with cisplatin (intraperitoneal administration of 5 mg/kg once a week for 4 weeks). (b) The body weights of the mice relative to their body weights at the beginning of treatments (day 15). (c) Representative photographs at the time of sacrifice of the peritoneal cavity of mice with ovarian cancer. White arrowheads point to specific tumors. The day of sacrifice is shown in brackets. Data for the control and C-Se groups are from two independent experiments (see text for details).
Nutrients 16 02249 g002
Nutrients 16 02249 g003aNutrients 16 02249 g003b
Figure 3. The anticancer activity of capecitabine and a diet lacking selenium in mice with metastatic colon cancer (CT26.WT cells inoculated in the tail vein of female BALB/cAnNRj mice). (a) The survival of mice treated with capecitabine (450 mg/kg/day; administered in the diet following a 7 days on/7 days off schedule for 2 or 3 cycles depending on their state of health), mice fed a normal standard diet, a control diet prepared from scratch, and a diet lacking selenium. (b) The body weights of the mice relative to their body weights at the beginning of treatments (day 4). Normal diet: standard rodent diet; control: control diet prepared from scratch; C-Se: diet without selenium.
Figure 3. The anticancer activity of capecitabine and a diet lacking selenium in mice with metastatic colon cancer (CT26.WT cells inoculated in the tail vein of female BALB/cAnNRj mice). (a) The survival of mice treated with capecitabine (450 mg/kg/day; administered in the diet following a 7 days on/7 days off schedule for 2 or 3 cycles depending on their state of health), mice fed a normal standard diet, a control diet prepared from scratch, and a diet lacking selenium. (b) The body weights of the mice relative to their body weights at the beginning of treatments (day 4). Normal diet: standard rodent diet; control: control diet prepared from scratch; C-Se: diet without selenium.
Nutrients 16 02249 g003aNutrients 16 02249 g003b
Nutrients 16 02249 g004
Figure 4. The anticancer activity of cisplatin and a diet lacking selenium in mice with metastatic triple-negative breast cancer (4T1 murine breast cancer cells inoculated in the tail vein of female BALB/cAnNRj mice). (a) The survival of mice treated with cisplatin (intraperitoneal administration of 5 mg/kg once a week for 4 weeks), mice fed a control diet prepared from scratch, and a diet lacking selenium. (b) The body weights of the mice relative to their body weights at the beginning of treatments (day 4). Control: control diet prepared from scratch; C-Se: diet without selenium.
Figure 4. The anticancer activity of cisplatin and a diet lacking selenium in mice with metastatic triple-negative breast cancer (4T1 murine breast cancer cells inoculated in the tail vein of female BALB/cAnNRj mice). (a) The survival of mice treated with cisplatin (intraperitoneal administration of 5 mg/kg once a week for 4 weeks), mice fed a control diet prepared from scratch, and a diet lacking selenium. (b) The body weights of the mice relative to their body weights at the beginning of treatments (day 4). Control: control diet prepared from scratch; C-Se: diet without selenium.
Nutrients 16 02249 g004
Table 1. In vivo metastatic cancer models.
Table 1. In vivo metastatic cancer models.
Cancer ModelMetastatic
Localization		Cell Line
Inoculation		Mice
(Sex, Train)		Positive
Control Drug		Treatment Start Day
Ovarian cancer Peritoneal dissemination5,000,000 ID8 Trp53−/− cells into the peritoneal cavityFemale C57BL/6JRjCisplatin 5 mg/kg i.p. once a week for 4 weeks15
Colon
cancer		Pulmonary metastases100,000 CT26.WT cells into the tail veinFemale BALB/cAnNRjCapecitabine 450 mg/kg/day in the diet 7/7 on/off schedule4
Triple-negative breast cancerPulmonary metastases100,000 4T1 cells into the tail veinFemale BALB/cAnNRjCisplatin 5 mg/kg i.p. once a week for 4 weeks4
Table 2. The composition of the six experimental diets (g/100 g dry diet).
Table 2. The composition of the six experimental diets (g/100 g dry diet).
DIETCC-SeC-ZnC-CuC-MnC-SZCM
Casein202020202020
Corn oil777777
Corn starch48.49848.49848.49848.49848.49848.498
Sucrose151515151515
Cellulose555555
Choline bitartrate0.250.250.250.250.250.25
Vitamin mix111111
Tert-butylhydroquinone0.00080.00080.00080.00080.00080.0008
Calcium carbonate1.001.001.001.001.001.00
Potassium phosphate monobasic0.880.880.880.880.880.88
Potassium citrate monohydrate0.0980.0980.0980.0980.0980.098
Sodium chloride0.260.260.260.260.260.26
Potassium sulphate0.160.160.160.160.160.16
Iron (III) citrate0.0280.0280.0280.0280.0280.028
Potassium iodate0.0000510.0000510.0000510.0000510.0000510.000051
Ammonium molybdate0.0000250.0000250.0000250.0000250.0000250.000025
Silicon dioxide0.00110.00110.00110.00110.00110.0011
Chromium (III) chloride hexahydrate0.000900.000900.000900.000900.000900.00090
Boric acid0.000290.000290.000290.000290.000290.00029
Magnesium oxide0.0840.0840.0840.0840.0840.084
Sodium fluoride0.000220.000220.000220.000220.000220.00022
Nickel (II) carbonate hydroxide tetrahydrate0.000110.000110.000110.000110.000110.00011
Ammonium metavanadate0.0000230.0000230.0000230.0000230.0000230.000023
Lithium chloride0.0000610.0000610.0000610.0000610.0000610.000061
Basic copper carbonate0.00110.00110.001100.00110
Basic zinc carbonate0.00550.005500.00550.00550
Manganese carbonate0.00240.00240.00240.002400
Sodium selenate0.00003600.0000360.0000360.0000360
C: control diet, C-Se: diet lacking selenium, C-Zn; diet lacking zinc, C-Cu: diet lacking copper, C-Mn: diet lacking manganese, C-SZCM: diet lacking selenium, zinc, copper, and manganese.
Table 3. Survival of mice with ovarian cancer treated with cisplatin or with diets lacking selenium, zinc, copper, manganese, or the four micronutrients.
Table 3. Survival of mice with ovarian cancer treated with cisplatin or with diets lacking selenium, zinc, copper, manganese, or the four micronutrients.
TreatmentnSurvival Time
(Mean ± SEM; Days)		Survival Improvement vs. Control (Days)p Value vs.
Control
Normal diet 652.5 ± 1.6--
Cisplatin (a)6>96.8 ± 19.0>+44.30.0015 (**)
Control (C)660.7 ± 2.2--
C-Se684.3 ± 13.7+23.60.2466
C-Zn658.5 ± 1.3−2.20.3659
C-Cu657.7 ± 1.6−3.00.3311
C-Mn658.7 ± 1.2−2.00.3311
C-SZCM667.3 ± 6.0+6.60.6864
Statistical analysis was calculated using the Gehan–Breslow–Wilcoxon test; ** indicates significance (p < 0.01). (a) Survival in the cisplatin group was compared with survival in the “Normal diet” group. n: sample size; SEM: standard error of the mean; normal diet: standard rodent diet; control (C): control diet prepared from scratch; C-Se: diet without selenium; C-Zn; diet without zinc; C-Cu: diet without copper; C-Mn: diet without manganese; C-SZCM: diet without selenium, zinc, copper, and manganese.
Table 4. The survival of mice with ovarian cancer treated with cisplatin or with the diet lacking selenium.
Table 4. The survival of mice with ovarian cancer treated with cisplatin or with the diet lacking selenium.
TreatmentnSurvival Time
(Mean ± SEM; Days)		Survival Improvement vs. Control (Days)p Value
vs. Control
Control (a) 1259.4 ± 1.3--
C-Se (a)1274.1 ± 7.514.70.0207 (*)
Cisplatin (b)483.5 ± 2.724.10.0061 (**)
Statistical analysis was calculated using the Gehan–Breslow–Wilcoxon test; * indicates significance (p < 0.05), ** indicates significance (p < 0.01). (a) Data from two independent experiments. (b) Data from one experiment. n: sample size; SEM: standard error of the mean; control: control diet prepared from scratch; C-Se: diet without selenium. Animals treated with cisplatin received the control diet prepared from scratch.
Table 5. Survival of mice with metastatic colon cancer treated with capecitabine or with diet lacking selenium.
Table 5. Survival of mice with metastatic colon cancer treated with capecitabine or with diet lacking selenium.
TreatmentnSurvival Time
(Mean ± SEM; Days)		Survival Improvement vs. Control (Days)p Value vs.
Control
Normal diet 530.0 ± 1.5--
Capecitabine (b)541.8 ± 2.7+11.80.0206 (*)
Control831.0 ± 1.4--
C-Se838.9 ± 3.8+7.90.0684
Statistical analysis was calculated using the Gehan–Breslow–Wilcoxon test; * indicates significance (p < 0.05). (b) Survival in the capecitabine group was compared with survival in the “Normal diet” group. n: sample size; SEM: standard error of the mean; normal diet: standard rodent diet; control: control diet prepared from scratch; C-Se: diet without selenium.
Table 6. Survival of mice with triple-negative breast cancer treated with cisplatin or with diet lacking selenium.
Table 6. Survival of mice with triple-negative breast cancer treated with cisplatin or with diet lacking selenium.
TreatmentnSurvival Time
(Mean ± SEM; Days)		Survival Improvement vs. Control (Days)p Value
vs. Control
Control 728.3 ± 2.2--
Cisplatin539.0 ± 4.7+10.70.1258
C-Se836.9 ± 6.9+8.60.9084
Statistical analysis was calculated using the Gehan–Breslow–Wilcoxon test. n: sample size; SEM: standard error of the mean; control: control diet prepared from scratch; C-Se: diet without selenium. Animals treated with cisplatin received the control diet prepared from scratch.
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Díaz-Ortega, P.; Calderón-Montaño, J.M.; Jiménez-Alonso, J.J.; Guillén-Mancina, E.; Jiménez-González, V.; Burgos-Morón, E.; López-Lázaro, M. A Diet Lacking Selenium, but Not Zinc, Copper or Manganese, Induces Anticancer Activity in Mice with Metastatic Cancers. Nutrients 2024, 16, 2249. https://doi.org/10.3390/nu16142249

AMA Style

Díaz-Ortega P, Calderón-Montaño JM, Jiménez-Alonso JJ, Guillén-Mancina E, Jiménez-González V, Burgos-Morón E, López-Lázaro M. A Diet Lacking Selenium, but Not Zinc, Copper or Manganese, Induces Anticancer Activity in Mice with Metastatic Cancers. Nutrients. 2024; 16(14):2249. https://doi.org/10.3390/nu16142249

Chicago/Turabian Style

Díaz-Ortega, Patricia, José Manuel Calderón-Montaño, Julio José Jiménez-Alonso, Emilio Guillén-Mancina, Víctor Jiménez-González, Estefanía Burgos-Morón, and Miguel López-Lázaro. 2024. "A Diet Lacking Selenium, but Not Zinc, Copper or Manganese, Induces Anticancer Activity in Mice with Metastatic Cancers" Nutrients 16, no. 14: 2249. https://doi.org/10.3390/nu16142249

APA Style

Díaz-Ortega, P., Calderón-Montaño, J. M., Jiménez-Alonso, J. J., Guillén-Mancina, E., Jiménez-González, V., Burgos-Morón, E., & López-Lázaro, M. (2024). A Diet Lacking Selenium, but Not Zinc, Copper or Manganese, Induces Anticancer Activity in Mice with Metastatic Cancers. Nutrients, 16(14), 2249. https://doi.org/10.3390/nu16142249

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop